Verismo Therapeutics to Present Clinical Trial Poster at ASCO 2025

Verismo Therapeutics, a clinical-stage company developing CAR T therapies based on its proprietary KIR-CAR technology, announced today that it will present a Trials in Progress poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 through June 3 in Chicago, Illinois. Details of the presentation are listed below.

KIR-CAR Platform Background

Verismo’s KIR-CAR platform represents a multi-chain approach to CAR T cell therapy, engineered to function effectively in suppressive tumor environments. The system uses NK cell-derived KIR receptors and DAP12 signaling chains, enabling a novel combination of activation and co-stimulation separate from conventional T cell pathways. This dual-signal architecture helps preserve CAR T cell function, maintain chimeric receptor expression, and minimize exhaustion, resulting in improved persistence and durable tumor control in preclinical models.

This technology has demonstrated the ability to reverse tumor growth in models resistant to standard CAR T therapies and opens up the potential for effective treatment of both hematologic malignancies and solid tumors.

About Verismo Therapeutics

A subsidiary of HLB Innovation, Verismo Therapeutics is advancing its first-in-class KIR-CAR platform through early-phase clinical development. Its leading candidates, SynKIR™-110 and SynKIR™-310, are currently undergoing Phase 1 trials. Verismo is the only biotechnology company developing this unique NK cell-based KIR-CAR system, which was designed to address critical gaps in the treatment of aggressive tumors and B cell-related disorders. For more information, visit: www.verismotherapeutics.com

Forward-Looking Statement Notice

This release contains forward-looking statements regarding the company’s expectations for clinical trials, regulatory milestones, product benefits, development strategies, and more. These statements are based on current assumptions and are subject to a range of risks and uncertainties that could lead to different actual outcomes. Risk factors include trial performance, regulatory approvals, market dynamics, funding, and product commercialization success. Verismo disclaims any obligation to revise these statements unless required by law.

SOURCE: Verismo Therapeutics